RL
RLMD.US Relmada Therapeutics Inc
- Market cap
- USD 378M
- P/E
- -
- P/B
- 2.18x
- ROE
- -31.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RLMD.US undervalued?
Graham numberThe Graham number of Relmada Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Relmada Therapeutics Inc fundamental analysis
No fundamental analysis for Relmada Therapeutics Inc yet.
Relmada Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, touret…
Full company profileRelmada Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Relmada Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -54.8K | -85.3K | -2.63K | -4.87K | -3.75K | -1.26K | - | - | - | - | - |
| Operating Income | -16.2M | -7.22M | -6.92M | -15.1M | -60.8M | -126M | -161M | -104M | -83.9M | -59.1M | -63.4M |
| EBITDA | -16.0M | -6.92M | -6.92M | -15.1M | -59.3M | -126M | -157M | 4.91M | -80.0M | -57.4M | -60.1M |
| Net Income | -2.98M | -6.29M | -8.96M | -15.0M | -59.5M | -126M | -157M | -98.8M | -80.0M | -57.4M | -61.1M |
| EPS | -1.03 | -2.08 | -2.86 | -1.63 | -3.81 | -7.16 | -5.30 | -3.28 | -2.65 | -1.45 | -0.54 |
| Balance Sheet | |||||||||||
| Total Assets | 10.2M | 2.84M | 3.05M | 117M | 118M | 223M | 153M | 97.6M | 45.8M | 94.0M | 205M |
| Total Liabilities | 3.20M | 1.38M | 8.56M | 1.46M | 12.6M | 15.1M | 12.5M | 12.2M | 10.3M | 7.49M | 11.6M |
| Shareholders' Equity | 7.04M | 1.46M | -5.51M | 116M | 106M | 208M | 140M | 85.4M | 35.5M | 86.5M | 194M |
| Cash & Short-term Investments | 8.50M | 1.71M | 2.24M | 116M | 117M | 212M | 148M | 96.3M | 44.9M | 93.0M | 202M |
| Total Debt | 274K | 2.93M | 2.94M | 110K | - | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -13.1M | -6.47M | -6.00M | -12.1K | -27.8M | -91.9M | -104M | -51.7M | -51.8M | -45.8M | -49.7M |
| Capital Expenditure | 562K | 49.7K | 12.4K | 0.00 | 0.00 | 5.00 | 3.00 | 4.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -13.7M | -6.52M | -6.01M | -12.1K | -27.8M | -91.9M | -104M | -51.7M | -51.8M | -45.8M | -49.7M |
| Ratios | |||||||||||
| ROE | -42.2% | -430.5% | - | -13.0% | -56.3% | -60.4% | -111.8% | -115.7% | -225.2% | -66.3% | -31.5% |
| ROA | -29.0% | -221.6% | -294.0% | -12.8% | -50.3% | -56.3% | -102.7% | -101.3% | -174.6% | -61.0% | -29.8% |
| Debt to Equity | 0.04x | 2.01x | - | 0.00x | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Relmada Therapeutics Inc dividends
Relmada Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:4 on Sep 30, 2019.
Who owns Relmada Therapeutics Inc
- Insiders 3.23%
- Institutions 96.77%
- Public & others 0.00%
- Shares outstanding 107M
- Free float 82.1M
Top funds holding RLMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.17M | 2.97% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 2.38M | 2.23% | 0.00% | Oct 2026 |
| Eventide Healthcare & Life Sciences I | 1.86M | 1.74% | +120.69% | Jun 2026 |
| Franklin Biotechnology Discv A(acc)USD | 1.46M | 1.37% | 0.00% | Sep 2026 |
| Polar Capital Biotech S Inc | 1.27M | 1.19% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 1.17M | 1.09% | +2.88% | Oct 2026 |
| Fidelity Small Cap Index | 1.04M | 0.97% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 875K | 0.82% | -0.38% | Oct 2026 |
| Biotech Growth Ord | 832K | 0.78% | -49.14% | Jul 2026 |
| Franklin Biotechnology Discovery A | 789K | 0.74% | 0.00% | Sep 2026 |
| AdvisorShares Psychedelics ETF | 643K | 0.60% | 0.00% | Oct 2026 |
| Vanguard Russell 2000 ETF | 550K | 0.52% | +1.24% | Sep 2026 |
| Fidelity Extended Market Index | 458K | 0.43% | -0.25% | Sep 2026 |
| iShares Micro-Cap ETF | 288K | 0.27% | 0.00% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 285K | 0.27% | +0.27% | Oct 2026 |
| Vanguard US Momentum Factor ETF | 274K | 0.26% | 0.00% | Sep 2026 |
| Vanguard Health Care ETF | 248K | 0.23% | +0.11% | Sep 2026 |
| Schwab Small Cap Index | 230K | 0.22% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 206K | 0.19% | -0.05% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 177K | 0.17% | 0.00% | Sep 2026 |
Top institutions holding RLMD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jupiter Topco LLC | 11.2M | 10.46% | 0.00% | Jun 2026 |
| BlackRock Inc | 7.43M | 6.96% | +475.92% | Jun 2026 |
| Squadron Capital Management LLC | 7.35M | 6.89% | -13.27% | Jun 2026 |
| VR Adviser, LLC | 6.84M | 6.41% | +41.31% | Jun 2026 |
| Spruce Street Capital LP | 6.39M | 5.99% | +2.06% | Jun 2026 |
| Adage Capital Partners Gp LLC | 4.76M | 4.46% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.46M | 4.18% | +44.97% | Jun 2026 |
| Jones Hill Capital LP | 3.66M | 3.43% | +966.39% | Jun 2026 |
| Orbimed Advisors LLC | 3.63M | 3.40% | -23.00% | Jun 2026 |
| State Street Corp | 2.52M | 2.36% | +605.12% | Jun 2026 |
| Geode Capital Management, LLC | 2.49M | 2.34% | +193.70% | Jun 2026 |
| Millennium Management LLC | 2.36M | 2.21% | -39.55% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 2.25M | 2.11% | -49.87% | Jun 2026 |
| Ikarian Capital, LLC | 2.15M | 2.01% | -20.09% | Jun 2026 |
| Driehaus Capital Management LLC | 2.13M | 2.00% | 0.00% | Jun 2026 |
| Ameriprise Financial Inc | 1.94M | 1.82% | +21.81% | Jun 2026 |
| Eventide Asset Management, LLC | 1.86M | 1.74% | +120.69% | Jun 2026 |
| Balyasny Asset Management LLC | 1.52M | 1.43% | +502.36% | Jun 2026 |
| StemPoint Capital LP | 1.46M | 1.37% | +22.20% | Jun 2026 |
| COMMODORE CAPITAL LP | 1.43M | 1.34% | +124.80% | Jun 2026 |
Relmada Therapeutics Inc company profile
- Company name
- Relmada Therapeutics Inc
- Ticker
- RLMD.US
- Exchange
- USA Stocks
- Listed since
- Oct 9, 2014
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 17
- Fiscal year end
- December
- Address
- 2222 Ponce de Leon Blvd., Coral Gables, FL, United States, 33134
- Phone
- 786 629 1376
- Website
- relmada.com
About Relmada Therapeutics Inc
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Relmada Therapeutics Inc management
8- Dr. Sergio Traversa M.B.A., Pharm.D.CEO & Director · born 1960
- Mr. Maged S. Shenouda M.B.A., R.Ph.Chief Financial Officer · born 1964
- Mr. Paul E. Kelly M.B.A.COO & Director · born 1957
- Mr. Charles S. Ence CPA, M.B.A.Chief Accounting & Compliance Officer · born 1965
- Ms. Gina DiGuglielmoVP & Head of Clinical Operations
- Dr. Bipin K. Dalmia MBA, Ph.D.Chief Business Officer
- Dr. Andrew CutlerSenior Clinical Development Advisor
- Dr. Richard M. Mangano Ph.D.Consultant · born 1950